Products - Menopause | Topic | NICE

Showing 4 products

Date | Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter

Fezolinetant for treating moderate to severe vasomotor symptoms associated with menopause (TA1143)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
31 March 2026
Estetrol for treating vasomotor symptoms associated with the menopause in people aged 40 to 65 [ID4037]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Elinzanetant for treating vasomotor symptoms associated with menopause [ID6359]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Elinzanetant for treating vasomotor symptoms caused by adjuvant endocrine treatment to prevent or treat hormone-receptor positive breast cancer [ID6544]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC